Drug
Cilengitide clinical trials
Also written EMD 121974.
- studies test it
- 27
- open now
- 0
- in phase 3
- 1
- first study started
- 1999
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
27 studies that test it; most in 2005 (4)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 2 |
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 4 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 4 |
| 2012 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 14
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 22
National Cancer Institute (NCI) (14) · EMD Serono (3) · Merck KGaA, Darmstadt, Germany (2) · Institut Claudius Regaud (1) · Centre Oscar Lambret (1) · Universitätsmedizin Mannheim (1) · Indiana University School of Medicine (1) · New Approaches to Brain Tumor Therapy Consortium (1)
Often tested with
Tested in the same studies.
Temozolomide (2) · Chemoradiotherapy (1) · Cisplatin (1) · Gemcitabine (1) · Vinorelbine (1) · Antineoplastic Agents (1) · Paclitaxel (1) · Cediranib (1)
Studies
Open first, then newest update. How each study uses Cilengitide is read from its arms, and is right about nine times in ten.
Testing it · 27
- Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung CancerCompletedPhase 1Institut Claudius RegaudNCT01118676Written as cilengitide, radiochemotherapy
- Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine GliomaCompletedPhase 1Centre Oscar LambretNCT01165333Written as Cilengitide
- Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung CancerCompletedPhase 1Universitätsmedizin MannheimNCT00884598Written as cilengitide
- Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)CompletedPhase 2EMD SeronoNCT00093964Written as Cilengitide 500 mg
- Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard TherapyCompletedPhase 2National Cancer Institute (NCI)NCT00679354Written as cilengitide
- Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)WithdrawnPhase 2M.D. Anderson Cancer CenterNCT01782976Written as Cilengitide
- Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma MultiformeTerminatedPhase 2National Cancer Institute (NCI)NCT00112866Written as cilengitide
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter StatusCompletedPhase 2EMD SeronoNCT00813943Written as Cilengitide (2-times weekly)
- Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)CompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT00842712Written as Cilengitide
- Cilengitide in Treating Patients With Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00121238Written as cilengitide
- Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT01276496Written as Cilengitide
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedPhase 1/2National Cancer Institute (NCI)NCT00085254Written as cilengitide
- Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and AdolescentsTerminatedPhase 2Martin-Luther-Universität Halle-WittenbergNCT01517776Written as Cilengitide
- Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedPhase 1National Cancer Institute (NCI)NCT01122888Written as Cilengitide
- Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent GlioblastomaCompletedPhase 1National Cancer Institute (NCI)NCT00979862Written as Cilengitide
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter StatusCompletedPhase 3EMD SeronoNCT00689221Written as Cilengitide
- EMD 121974 in Treating Patients With Locally Advanced or Metastatic CancerCompletedPhase 1Indiana University School of MedicineNCT00004258Written as cilengitide
- Pharmacokinetics in Subjects With Renal ImpairmentCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT01504165Written as cilengitide 2000mg
- Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00063973Written as cilengitide
- EMD 121974 in Treating Patients With Progressive or Recurrent GliomaCompletedPhase 1/2New Approaches to Brain Tumor Therapy ConsortiumNCT00006093Written as cilengitide
See all 27 studies that test Cilengitide →
Given in every arm · 1 — Cilengitide is usual care beside what is tested
Codes
What other systems call Cilengitide · ClinicalTrials.gg INT004322
- MeSH (NLM) C422910CilengitideConfirmed NLM, Wikidata
- UNII (FDA) 4EDF46E4GICILENGITIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q1091921cilengitideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1834CilengitideOne source FDA
- DrugBank DB11890One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C422910 | Cilengitide | Confirmed NLM, Wikidata |
| UNII (FDA) | 4EDF46E4GI | CILENGITIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q1091921 | cilengitide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1834 | Cilengitide | One source FDA |
| DrugBank | DB11890 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.